Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IRWD Stock Forecast 2025-2026
$0.62
Current Price
$99.07M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to IRWD Price Targets
+77.4%
To High Target of $1.10
+61.3%
To Median Target of $1.00
+12.9%
To Low Target of $0.70
IRWD Price Momentum
+8.8%
1 Week Change
-29.5%
1 Month Change
-89.6%
1 Year Change
-86.0%
Year-to-Date Change
-91.3%
From 52W High of $7.11
+17.0%
From 52W Low of $0.53
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Ironwood (IRWD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IRWD and similar high-potential opportunities.
Latest IRWD Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, IRWD has a neutral consensus with a median price target of $1.00 (ranging from $0.70 to $1.10). Currently trading at $0.62, the median forecast implies a 61.3% upside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Amy Li at Jefferies, suggesting a 12.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IRWD Analyst Ratings
0
Buy
4
Hold
0
Sell
IRWD Price Target Range
Low
$0.70
Average
$1.00
High
$1.10
Current: $0.62
Latest IRWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IRWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Downgrade | $1.00 |
| Apr 15, 2025 | Jefferies | Amy Li | Hold | Downgrade | $0.70 |
| Apr 14, 2025 | Leerink Partners | Faisal Khurshid | Market Perform | Maintains | $1.00 |
| Jan 30, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $14.00 |
| Jan 22, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $8.00 |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Market Perform | Initiates | $5.00 |
| Aug 9, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $10.00 |
| Aug 9, 2024 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $12.00 |
| May 10, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $14.00 |
| Mar 1, 2024 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $14.00 |
| Feb 16, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $21.00 |
| Jan 17, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $21.00 |
| Dec 14, 2023 | Wells Fargo | Mohit Bansal | Overweight | Initiates | $20.00 |
| Sep 28, 2023 | JMP Securities | Jason Butler | Market Outperform | Initiates | $22.00 |
| May 23, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $19.00 |
| Aug 29, 2022 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Aug 16, 2022 | Wells Fargo | Jacob Hughes | Equal-Weight | Maintains | $13.00 |
| Apr 22, 2022 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Oct 12, 2021 | Morgan Stanley | David Lebowitz | Equal-Weight | Maintains | $14.00 |
| Jul 16, 2021 | Morgan Stanley | David Lebowitz | Equal-Weight | Maintains | $12.00 |
Ironwood Pharmaceuticals Inc. (IRWD) Competitors
The following stocks are similar to Ironwood based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ironwood Pharmaceuticals Inc. (IRWD) Financial Data
Ironwood Pharmaceuticals Inc. has a market capitalization of $99.07M with a P/E ratio of 92.7x. The company generates $317.68M in trailing twelve-month revenue with a -10.2% profit margin.
Revenue growth is -45.1% quarter-over-quarter, while maintaining an operating margin of -25.6% and return on equity of -0.3%.
Valuation Metrics
Market Cap
$99.07M
Enterprise Value
$585.91M
P/E Ratio
92.7x
PEG Ratio
1.6x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-45.1%
Gross Margin
N/A
Operating Margin
-25.6%
Net Margin
-10.2%
EPS Growth
-45.1%
Financial Health
Cash/Price Ratio
+108.1%
Current Ratio
3.3x
Debt/Equity
-1.8x
ROE
-0.3%
ROA
+12.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ironwood Pharmaceuticals Inc. (IRWD) Business Model
About Ironwood Pharmaceuticals Inc.
What They Do
Develops drugs for gastrointestinal conditions.
Business Model
Ironwood Pharmaceuticals operates by developing and commercializing innovative drugs specifically for gastrointestinal disorders. It generates revenue primarily through the sales of its flagship product, Linzess, which targets conditions like IBS-C and CIC. The company also pursues partnerships to enhance its drug development pipeline and market presence.
Additional Information
Headquartered in Cambridge, Massachusetts, Ironwood is dedicated to addressing unmet medical needs and improving patient outcomes. Its strategic focus on novel treatments positions it competitively within the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
253
CEO
Mr. Thomas A. McCourt
Country
United States
IPO Year
2010
Website
ironwoodpharma.comIronwood Pharmaceuticals Inc. (IRWD) Latest News & Analysis
Latest News
Quick Summary
Ironwood reports a wider-than-expected loss in Q1 2025, with revenues declining significantly compared to the previous year.
Why It Matters
Wider losses and declining revenues signal potential financial instability for Ironwood, raising concerns about future profitability and investment viability.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong demand for LINZESS in Q1 2025, raising its adjusted EBITDA guidance and maintaining its full-year outlook.
Why It Matters
Strong demand for LINZESS and raised EBITDA guidance indicate healthy growth potential for Ironwood Pharmaceuticals, which may lead to increased investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ironwood Pharmaceuticals (IRWD) reported a quarterly loss of $0.14 per share, exceeding the Zacks estimate of a $0.05 loss, compared to a $0.02 loss per share a year ago.
Why It Matters
Ironwood Pharmaceuticals' larger-than-expected quarterly loss may signal financial struggles, potentially affecting stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
22 days ago
Quick Summary
Ironwood (IRWD) is unlikely to achieve an earnings beat in its upcoming report due to missing key performance indicators. Investors should prepare for this announcement.
Why It Matters
Ironwood's lack of key ingredients for an earnings beat signals potential underperformance, which may negatively impact its stock price and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Ironwood Pharmaceuticals (Nasdaq: IRWD) will participate in a fireside chat at The Citizens Life Sciences Conference on May 7 at 12:00 p.m. ET, with a live webcast available on their website.
Why It Matters
Ironwood Pharmaceuticals' participation in a prominent conference could signal potential insights into its strategic direction and performance, influencing investor sentiment and stock movements.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ironwood Pharmaceuticals reaffirmed its 2025 U.S. net sales guidance for LINZESS and raised its adjusted EBITDA guidance. Full Q1 2025 results will be reported in early May.
Why It Matters
Ironwood's reaffirmation of 2025 sales guidance and raised EBITDA expectations signal confidence in growth, potentially boosting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About IRWD Stock
What is Ironwood Pharmaceuticals Inc.'s (IRWD) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Ironwood Pharmaceuticals Inc. (IRWD) has a median price target of $1.00. The highest price target is $1.10 and the lowest is $0.70.
Is IRWD stock a good investment in 2025?
According to current analyst ratings, IRWD has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IRWD stock?
Wall Street analysts predict IRWD stock could reach $1.00 in the next 12 months. This represents a 61.3% increase from the current price of $0.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ironwood Pharmaceuticals Inc.'s business model?
Ironwood Pharmaceuticals operates by developing and commercializing innovative drugs specifically for gastrointestinal disorders. It generates revenue primarily through the sales of its flagship product, Linzess, which targets conditions like IBS-C and CIC. The company also pursues partnerships to enhance its drug development pipeline and market presence.
What is the highest forecasted price for IRWD Ironwood Pharmaceuticals Inc.?
The highest price target for IRWD is $1.10 from at , which represents a 77.4% increase from the current price of $0.62.
What is the lowest forecasted price for IRWD Ironwood Pharmaceuticals Inc.?
The lowest price target for IRWD is $0.70 from Amy Li at Jefferies, which represents a 12.9% increase from the current price of $0.62.
What is the overall IRWD consensus from analysts for Ironwood Pharmaceuticals Inc.?
The overall analyst consensus for IRWD is neutral. Out of 14 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are IRWD stock price projections?
Stock price projections, including those for Ironwood Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 5:32 PM UTC